Home > Boards > Free Zone > User's Groups > Awesome Stocks

Landmark Study Proves COVID Vaccines Much Less Effective

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
bigworld Member Profile
 
Followed By 31
Posts 7,740
Boards Moderated 0
Alias Born 12/15/04
160x600 placeholder
Top Company News of the Day
The waiver allows Credit Suisse's investment adviser affiliates to keep doing business following an SEC settlement, but the Republican says some requirements could be harmful.
Canada Antitrust Watchdog Probes Google Conduct in Online Ad Market -- Update
Canada Antitrust Watchdog Probes Google Conduct in Online Ad Market
USDA Reports Drop in Cattle Placed on Market
Wheat Rises on Tighter Supply Picture -- Daily Grain Highlights
Warren Buffett Tenders Cattolica Stake as Generali Takeover Edges Closer, Source Says
Front Month Nymex Natural Gas Fell 2.40% This Week to Settle at $5.2800 -- Data Talk
Front Month Nymex RBOB Gasoline Fell 0.17% This Week to Settle at $2.4821 -- Data Talk
Trustmark National Bank To Pay $5 Million To Settle Lending Discrimination Claims
3Q GDP Seen +3.0% -- Data Week Ahead
U.S. Oil-Rig Count Falls by Two in Latest Week, Baker Hughes Says
American Express on Track for Record High Close -- Data Talk
UK Takeover Panel Suspends Timetable on Ganfeng's Offer for Bacanora Lithium
S&P Global, IHS Markit Get Conditional Approval From European Commission for Deal
FTSE 100 Closed Up as It Shrugs off the Week's Negative Sentiment
STOXX Europe 50 Index Ends the Week 0.25% Higher at 3637.18 -- Data Talk
EURO STOXX 50 Index Ends the Week 0.14% Higher at 4188.81 -- Data Talk
STOXX Europe 600 Index Ends the Week 0.53% Higher at 471.88 -- Data Talk
FTSE 100 Index Ends the Week 0.41% Lower at 7204.55 -- Data Talk
DAX Ends the Week 0.28% Lower at 15542.98 -- Data Talk
CAC 40 Index Ends the Week 0.09% Higher at 6733.69 -- Data Talk
S&P Global's Acquisition of IHS Markit Gets Conditional Green Light From EU
Walmart on Track for Longest Winning Streak Since September 2019 -- Data Talk
Snap Inc. Down Over 23%, on Track for Record Percent Decrease -- Data Talk
Watchdog Criticizes FAA Oversight Of American Airlines Maintenance
Creatd Shares Jump After Unit Signs Alexis LaRue
bigworld   Thursday, 08/19/21 03:00:14 PM
Re: gfp927z post# 55
Post # of 190 
Landmark Study Proves COVID Vaccines Much Less Effective Than Advertised

BY TYLER DURDEN
THURSDAY, AUG 19, 2021 - 09:45 AM

The largest study yet to examine the efficacy of COVID vaccines in the wild has just been published by the University of Oxford and UK Office for National Statistics, and unsurprisingly it found that the efficacy rates for the Pfizer and Moderna are significantly lower than the 90%+ rates first advertised from the initial controlled trials.

According to the study, a preprint of which was published on Thursday, while the Pfizer, Moderna and AstraZeneca jabs still offer "good" protection against new infections, their efficacy has been reduced compared with Alpha. While having two doses of either vaccine still provides "at least the same level of protection as having had COVID-19", those who were vaccinated after already being infected demonstrated even higher levels of protection than those who either weren't infected and only received the jabs, or were infected, but didn't receive the jabs.

"We’re seeing here the real-world data of how two vaccines are performing, rather than clinical trial data, and the data sets all show how the delta variant has blunted the effectiveness of both the Pfizer and AstraZeneca jabs," said Simon Clarke, an associate professor in cellular microbiology at the University of Reading.

Despite all this, even after receiving two doses of a jab, those infected with delta showed much higher peak levels of the virus than those infected with alpha, or some other variant.

The study also highlighted differences between between vaccines: for example, the Moderna jab had "similar or greater effectiveness" against the delta variant as a single dose of the other vaccines. And while the Pfizer and Moderna jabs showed greater initial efficacy against infection than the AstraZeneca jab, this protection premium erodes after only 4-5 months.

The data also showed that delta increases transmissibility more than other COVID varients, even among the vaccinated, which backs up a recent assessment made by the American CDC.

The results raise more doubt about the possibility of ever achieving herd immunity via vaccination, said Sarah Walker, a professor of medical statistics and epidemiology at Oxford, who helped lead the study. That's not exactly a surprise.

Finally, one important piece of the puzzle that’s still missing is the data relating to hospitalizations and severe cases of COVID, according to Penny Ward, a visiting professor in pharmaceutical medicine at King’s College London, who wasn’t involved with the study, and spoke to Bloomberg about its results. It's possible the findings could support "cross-vaccination" with different types of jabs, which could offer more comprehensive protection, she said.



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences